High Hematocrit and Hemoglobin: What's Actually Driving It, and What the Research Says About Fixing It

Elevated hematocrit (the percentage of blood volume made up of red blood cells) and hemoglobin is the single most common lab abnormality flagged during testosterone therapy, and it's also one of the most misunderstood. The number itself is simple. What's actually driving it, and what to do about it, is a genuinely more complicated research picture than "just donate blood." Why TRT Raises Hematocrit in the First Place Testosterone stimulates red blood cell production (erythropoiesis) through a well-characterized mechanism: it triggers an initial rise in erythropoietin (EPO, the hormone that signals the bone marrow to make more red blood cells), establishes a new, higher EPO/hemoglobin "set point," and simultaneously suppresses hepcidin — the body's master iron-regulating hormone. Lower hepcidin means more iron becomes available for the bone marrow to use, feeding the increased red blood cell production testosterone has already triggered. This effect is dose-dependent and more pronounced in older men. It's also meaningfully affected by the type of testosterone therapy: short-acting injectable formulations (like testosterone cypionate or enanthate given every 1-2 weeks) that produce a sharp peak followed by a longer decline are associated with substantially higher erythrocytosis risk than formulations that maintain steadier levels, because the transient supraphysiological peak is a stronger stimulus than staying within a normal range. Hydration: What It Actually Changes (and What It Doesn't) This is where a lot of confusion sits. Dehydration causes something called spurious or relative erythrocytosis: your actual red blood cell mass hasn't changed, but with less plasma (the liquid portion of blood) diluting it, the percentage that reads as red blood cells goes up. A well-hydrated blood draw gives a more accurate picture of your true hematocrit; a dehydrated one can show a falsely elevated number that doesn't reflect a real increase in red cell mass. Clinical guidance on evaluating elevated hematocrit explicitly lists ruling out dehydration as a first step before assuming true erythrocytosis. The honest implication: showing up well-hydrated to a blood draw gives you (and your doctor) a more accurate number, but it isn't treating anything. If your hematocrit is genuinely elevated from testosterone's effect on erythropoiesis, drinking more water beforehand just makes the lab draw more accurate — it doesn't change the actual amount of red blood cells your body has made. Phlebotomy: The Guideline That's Currently Being Challenged Here's where the research has gotten genuinely more complicated in just the last couple of years. The traditional approach — and still the standard recommendation from the Endocrine Society and American Urological Association — is to withhold testosterone therapy when hematocrit exceeds roughly 54%, resume at a lower dose once it normalizes, and use therapeutic phlebotomy (essentially the same process as donating blood) as an effective tool for bringing hematocrit down in the meantime. But a 2024 paper directly challenged whether that's actually a good idea for this specific type of erythrocytosis. The authors point out that evidence supporting phlebotomy's efficacy or safety specifically for TRT-induced erythrocytosis is lacking, and raise a genuinely concerning hypothesis: phlebotomy lowers tissue oxygen levels and depletes iron stores, both of which can activate a cellular oxygen-sensing pathway (HIF, hypoxia-inducible factor) that further increases EPO production — potentially recreating the same erythrocytosis it was meant to treat, while also increasing thrombotic risk through mechanisms independent of hematocrit itself. Their recommendation is that phlebotomy should be a shared decision between patient and physician, weighing this real uncertainty, rather than an automatic response to a number above threshold. This connects directly to the iron and ferritin question: repeated phlebotomy depletes iron stores over time (this is well established; it's the same reason regular blood donors are monitored for iron deficiency). Whether that iron depletion is a harmless tradeoff or an active contributor to the biological pathway driving erythrocytosis in the first place is exactly the open question the 2024 research is raising. This is not a settled debate, and it's worth knowing that the "just go donate blood" advice is currently being questioned in the literature, not confirmed. Sleep Apnea: A Real but More Nuanced Contributor Than Often Assumed Obstructive sleep apnea (OSA) is a well-established cause of secondary erythrocytosis on its own, independent of testosterone: intermittent nighttime hypoxia triggers the same EPO pathway, and a meta-analysis pooling multiple studies found OSA patients have a higher prevalence of secondary polycythemia, with CPAP treatment measurably reducing both hemoglobin and hematocrit. Where it gets more nuanced: one large study specifically testing this relationship found that hematocrit and erythrocytosis weren't actually associated with OSA severity (measured by apnea-hypopnea index) as strongly as expected — they were more strongly associated with the degree of hypoxemia itself, both during waking hours and, to a lesser extent, at night. The practical implication is that OSA severity scores alone don't reliably predict who will develop erythrocytosis; actual oxygen desaturation levels matter more, which is part of why unexplained erythrocytosis (especially in men also on TRT, where two contributing causes can stack) is a recognized reason to pursue a sleep study with nocturnal oximetry, not just assume TRT is the sole cause. How This Actually Gets Sorted Out in Practice Based on the research above, working through unexplained or persistent high hematocrit typically involves several distinct questions, not one fix: Is the reading accurate? Ruling out dehydration and confirming trough-timed lab draws (immediately before the next dose, not at the post-injection peak) prevents chasing a falsely elevated number. Is testosterone dosing or formulation contributing? Research comparing formulations consistently finds that short-acting injections with sharp peaks carry more erythrocytosis risk than steadier delivery methods; dose reduction or switching to a formulation with smaller peak-to-trough variation are both discussed in the literature as ways to lower risk without necessarily stopping therapy. Is something else driving it independently? Sleep apnea is the most common overlooked contributor and is worth ruling out with a sleep study if hematocrit stays elevated despite reasonable testosterone dosing. Checking a serum EPO level and, in ambiguous or higher-hemoglobin cases, JAK2 mutation testing helps rule out primary polycythemia (a different, bone-marrow-driven condition) rather than assuming testosterone or sleep apnea are the only possible explanations. Is phlebotomy actually the right tool here? Given the 2024 research above, this is now a genuine shared decision between patient and physician rather than an automatic response, weighing the established benefit of lowering hematocrit against the more theoretical, but real, concern about iron depletion and HIF-driven effects. The Bottom Line High hematocrit on TRT has a well-understood biological cause (the EPO/hepcidin pathway), but the two most common "solutions" people reach for — hydrating better and donating blood — deserve more precision than they usually get. Hydration improves the accuracy of the number without changing the underlying red cell mass. Phlebotomy is an established but increasingly debated tool whose iron-depleting effects may carry tradeoffs the field is still actively working out. Sleep apnea is a real, separate contributor that's easy to miss, especially since it doesn't always track with how severe the apnea itself is. None of this is a do-it-yourself protocol adjustment — it's exactly the kind of layered, individualized question that belongs in a real conversation with a physician who can order the right tests (trough testosterone, EPO, sleep study if warranted) rather than reacting to a single hematocrit number in isolation.